跳转至内容
Merck

1044651

USP

阿托伐醌

United States Pharmacopeia (USP) Reference Standard

别名:

Mepron, 反式-2-[4-(4-氯苯基)环己基]-3-羟基-1,4-萘二酮

登录查看公司和协议定价


About This Item

经验公式(希尔记法):
C22H19ClO3
CAS号:
分子量:
366.84
分類程式碼代碼:
41116107
NACRES:
NA.24

等級

pharmaceutical primary standard

API 家族

atovaquone

製造商/商標名

USP

應用

pharmaceutical (small molecule)

格式

neat

儲存溫度

2-8°C

SMILES 字串

OC1=C([C@H]2CC[C@@H](CC2)c3ccc(Cl)cc3)C(=O)c4ccccc4C1=O

InChI

1S/C22H19ClO3/c23-16-11-9-14(10-12-16)13-5-7-15(8-6-13)19-20(24)17-3-1-2-4-18(17)21(25)22(19)26/h1-4,9-13,15,26H,5-8H2/t13-,15-

InChI 密鑰

KUCQYCKVKVOKAY-CTYIDZIISA-N

正在寻找类似产品? 访问 产品对比指南

一般說明

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

應用

Atovaquone USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia. Also, for use with USP monographs such as:
  • Atovaquone Oral Suspension

生化/生理作用

阿托伐醌是一种抗原生动物线粒体电子传递抑制剂;抗疟药;抗肺囊虫药,也已用于治疗弓形虫病。它是原生动物线粒体蛋白泛醌的类似物,并通过与泛醇氧化口袋中的Rieske铁硫蛋白和细胞色素b相互作用抑制细胞色素bc(1)复合物起作用。

分析報告

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.  ​

其他說明

Sales restrictions may apply.

儲存類別代碼

11 - Combustible Solids

水污染物質分類(WGK)

WGK 3

閃點(°F)

Not applicable

閃點(°C)

Not applicable


分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ (Lot或Batch)字后找到。

已有该产品?

在文件库中查找您最近购买产品的文档。

访问文档库

Shirly Grynberg et al.
The American journal of tropical medicine and hygiene, 92(1), 13-17 (2014-11-06)
Atovaquone-proguanil (AP) and artemether-lumefantrine (AL) are both treatments for uncomplicated Plasmodium falciparum malaria, but comparative clinical trials are lacking. We performed a retrospective analysis, comparing treatment failure and fever clearance time in non-immune travelers with uncomplicated P. falciparum malaria, treated
Geoffrey W Birrell et al.
Antimicrobial agents and chemotherapy, 59(1), 170-177 (2014-10-22)
4-(tert-Butyl)-2-((tert-butylamino)methyl)-6-(6-(trifluoromethyl)pyridin-3-yl)-phenol (JPC-2997) is a new aminomethylphenol compound that is highly active in vitro against the chloroquine-sensitive D6, the chloroquine-resistant W2, and the multidrug-resistant TM90-C2B Plasmodium falciparum lines, with 50% inhibitory concentrations (IC50s) ranging from 7 nM to 34 nM. JPC-2997
L M Upton et al.
Antimicrobial agents and chemotherapy, 59(1), 490-497 (2014-11-12)
To achieve malarial elimination, we must employ interventions that reduce the exposure of human populations to infectious mosquitoes. To this end, numerous antimalarial drugs are under assessment in a variety of transmission-blocking assays which fail to measure the single crucial
Sanna R Rijpma et al.
Malaria journal, 13, 359-359 (2014-09-15)
Therapeutic blood plasma concentrations of anti-malarial drugs are essential for successful treatment. Pharmacokinetics of pharmaceutical compounds are dependent of adsorption, distribution, metabolism, and excretion. ATP binding cassette (ABC) transport proteins are particularly involved in drug deposition, as they are located
F Giallongo et al.
Journal of dairy science, 98(5), 3292-3308 (2015-03-03)
This experiment was conducted with the objective to investigate the effects of slow-release urea and rumen-protected (RP) Met and His supplementation of a metabolizable protein (MP)-deficient diet (according to NRC, 2001) on lactation performance of dairy cows. Sixty lactating Holstein

我们的科学家团队拥有各种研究领域经验,包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门